| Recruiting | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and In NCT07524114 | University Health Network, Toronto | — |
| Suspended | Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila NCT07111039 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Not Yet Recruiting | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study NCT07389525 | Indiana University | EARLY_Phase 1 |
| Recruiting | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial NCT07447050 | University of California, Irvine | Phase 2 |
| Recruiting | Discharge Medication Use Post-Operatively in GU Cancer Patients NCT06795087 | Wake Forest University Health Sciences | — |
| Recruiting | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial NCT06580002 | University of California, Irvine | Phase 2 |
| Active Not Recruiting | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction NCT06253520 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptabil NCT06168825 | Inova Health Care Services | — |
| Completed | Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy NCT05707286 | Indiana University | — |
| Recruiting | High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins NCT06835426 | Algemeen Ziekenhuis Maria Middelares | N/A |
| Unknown | Adapting the Tumor Board Model for Mental Illness and Cancer NCT05837598 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC) NCT05629065 | Dana-Farber Cancer Institute | N/A |
| Recruiting | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies NCT04923178 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Impact of COVID-19 on GU Disease NCT04761107 | Icahn School of Medicine at Mount Sinai | — |
| Recruiting | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) NCT04235777 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity NCT04273061 | British Columbia Cancer Agency | Phase 2 |
| Completed | Parametric PET of Genitourinary Cancer NCT04020978 | University of California, Davis | N/A |
| Recruiting | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors NCT04354064 | Washington University School of Medicine | — |
| Active Not Recruiting | An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking Ab NCT03794635 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer NCT03480152 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors NCT03333616 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation NCT02906943 | University Health Network, Toronto | — |
| Active Not Recruiting | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer NCT02735252 | University of California, San Francisco | N/A |
| Completed | Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (P NCT02583815 | University of Texas Southwestern Medical Center | — |
| Completed | A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients NCT02222259 | University of Toronto | N/A |
| Completed | Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) NCT02060370 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Personal Web Page In Clinical Trial Participant Education NCT03887091 | Dana-Farber Cancer Institute | N/A |
| Completed | Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial) NCT02140463 | Samsung Medical Center | — |
| Recruiting | Genomic Investigation of Unusual Responders NCT03740503 | University Health Network, Toronto | — |
| Completed | Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass NCT01433302 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Integrated Molecular Profiling in Advanced Cancers Trial NCT01505400 | University Health Network, Toronto | — |
| Completed | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers NCT01375699 | Virginia Commonwealth University | Phase 1 |
| Terminated | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contra NCT00147238 | M.D. Anderson Cancer Center | N/A |